Edwards to supply Interpore's AGF (autologous growth factor) products:
This article was originally published in Clinica
Executive Summary
Edwards Lifesciences Cardiovascular Resources is to supply Interpore Cross' autologous growth factor (AGF) related products to US hospitals where it provides contract perfusion and autotransfusion services. AGF is a concentrate of growth factors that enhances bone growth and healing derived from the patient's blood. The companies, both based in Irvine, California, did not reveal financial details of the three-year, exclusive agreement. David Mercer, CEO of Interpore Cross, said: "While we continue to focus on bone grafting procedures, we believe Edwards' leading position in the market for perfusion and autotransfusion services may also help us gain exposure to a variety of wound healing applications."
You may also be interested in...
Executives On The Move: Changes At The Top At Enzolytics, Dyne Therapeutics And Seres Therapeutics
Recent moves in the industry include new chief financial officers at LENZ Therapeutics and Botanix Pharmaceuticals, plus new chief medical officers at Vigil Neuroscience and Voyager Therapeutics.
Israel's Gamida Cell Survives By Selling To Lender
Having finally secured US approval for Omisirge, Gamida was hoping to bag a strategic partner for the cell therapy. A year on, no suitable partner has been identified and the firm is delisting from the NASDAQ and going private.
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.